Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids

Shrader, Sarah H.; Tong, Yongliang; Duff, Maxwell B.; Freedman, Jonathan H.; Song, Zhao-Hui

doi:10.1016/j.bbrc.2020.10.021

Cited by 13 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For a better understanding of the origins of these observed effects, it is possible to hypothesize that CBD's multi-target pharmacological properties, such as stimulation of serotonergic and dopaminergic neuron firing, could explain them (French et al, 1997;De Gregorio et al, 2019). CBD has been shown to have a partial agonistic action on dopamine D2-like receptors, an action that may block the D2 receptors when they are overreactive or activate them when they are underactive (Shrader et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Pharmacovigilance on cannabidiol as an antiepileptic agent

et al. 2023

View full text Add to dashboard Cite

Introduction: Cannabidiol (CBD) is an active chemical contained in the plant Cannabis sativa. It is a resorcinol-based compound that crosses the blood-brain barrier without causing euphoric effects. CBD has a plethora of pharmacological effects of therapeutic interest. CBD has been authorized in the European Union as an anticonvulsant against serious infantile epileptic syndromes, but its safety profile is still not sufficiently described.Methods: With the goal of expanding information on the safety of CBD use as an antiepileptic agent beyond the most common side effects known through clinical studies, an analysis of serious case reports on suspected adverse reactions (SARs) to CBD licensed as an anti-epileptic drug found in the EudraVigilance database is reported in this article. EudraVigilance is a system purchased by the European Medicines Agency (EMA) for monitoring the safety of medicinal products marketed in Europe.Results: The most frequent serious SARs to CBD in EudraVigilance were epilepsy aggravation, hepatic disorders, lack of efficacy, and somnolence.Discussion: Based on our analysis, the following precautions should be adopted for appropriate monitoring of potential adverse effects, more attention towards possible CBD medical use as an antiepileptic: awareness of interactions with other drugs, epilepsy aggravation, and drug effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacovigilance on cannabidiol as an antiepileptic agent

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The products extracted from the cannabis plant consist of a large number of Phytocannabinoids, a term used to differentiate cannabinoids derived from the plant, from those found in the body (i.e., endocannabinoids) or those chemically synthesized (i.e., endocannabinoids or exo-CBs), of about 100 phyto-CBs contained in the plant there are two significant ones, namely cannabidiol (CBD) and delta-9-Tetrahydrocannabinol (∆9-THC). Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC, THC) are the major constituents of marijuana 31 among the cannabinoids. Δ9-THC is a psychoactive agent with analgesic and muscle relaxant properties, whereas CBD is a nonpsychoactive compound that is shown to have hypnotic, anxiolytic, antipsychotic, antioxidant, and neuroprotective effects 32 , THC is a partial agonist at the cannabinoid receptor 1 (CB1) and receptor 2 (CB2).…”

Section: Role Of Endocannabinoidmentioning

confidence: 99%

Untitled

2022

IJPSR

View full text Add to dashboard Cite

As new treatments and medication are growing rapidly, neurologists are also toward expanding treating patients with idiopathic Parkinson's disease and facing questions regarding cannabis as a treatment elective, particularly for levodopa-safe Parkinson's symptoms. Cannabinoids compounds like delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are the most abundant chemicals present. Whereas THC is psychotropic chemical that tends to cause individuals to feel "high," while CBD is no psychotropic chemical. Nonetheless, other than cannabis, plant cannabinoids are also produced by the mammalian body, called endocannabinoids. Endocannabinoids are neurotransmitters that bind to cannabinoid receptors and cannabinoid receptor proteins expressed throughout the central nervous system, including the brain and peripheral nervous system. So, these endocannabinoid receptors can be of two types cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), which are G-protein coupled receptors. The first receptor, CB1R receptors are particularly abundant in the hippocampus, frontal cortex, basal ganglia, hypothalamus and cerebellum, spinal cord and peripheral nervous system. They can also be found in inhibitory GABA-ergic neurons and excitatory glutamatergic neurons. Whereas CB2R receptor is most abundantly found on cells of the immune system hematopoietic cells and glial cells. CB2R receptor is mainly found in the periphery under normal healthy conditions, but in the case due to disease or injury, this regulation occurs within the brain, and CB2R is therefore expressed in the brain in disease or injured person. INTRODUCTION:The most common neurodegenerative disorder can be said as Parkinson's disease (PD). PD is the gradual loss of dopaminergic neurons that destroy the basal ganglia, which is an important part of the brain for coordinated movement. Patients with PD experience motor symptoms, including bradykinesia (slowness and poverty of movement), resting tremor, muscular rigidity, and gait (impairment of postural balance).

show abstract

“…Although it has a low affinity for these receptors, it is nevertheless interesting that CBD may favor increases in endogenous endocannabinoid levels by indirect mechanisms. However, its actions are much more varied: for example, it intervenes in modulating the activity of some neurotransmitter transporters such as dopamine, norepinephrine, adenosine, and glutamate [84,138].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

“…CBD, CBDA, and CBDV have been found to have numerous beneficial effects on the relief of various symptoms, especially in central nervous system disorders. CBD was tested in various neurological disorders such as depression and mood disorders, schizophrenia, Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and Alzheimer's, and in other types of pathologies such as neuropathic pain and inflammation [29,87,91,135,138,140,141]. CBDV has also become a good candidate as a therapeutic agent for neurological diseases such as epilepsy and autism spectrum disorders, Rett syndrome, ischemic strokes, or inflammatory pathologies such as inflammatory bowel disease (IBD) [91,[142][143][144].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

et al. 2021

View full text Add to dashboard Cite

The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors. Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, transient receptor ankyrin 1 potential, peroxisome proliferator-activated receptor-gamma or glitazone receptor, G55 protein-coupled receptor, and nuclear receptor, producing pharmacological effects in diseases such as Alzheimer’s, epilepsy, depression, neuropathic pain, cancer, and diabetes. Nonetheless, further studies are needed to elucidate the precise mechanisms of these compounds. Structure modulation of phytocannabinoids, in order to improve pharmacological effects, should not be limited to the exploration of cannabinoid receptors, and it should target other courses of action discovered through recent research.

show abstract

Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids

Cited by 13 publications

References 29 publications

Pharmacovigilance on cannabidiol as an antiepileptic agent

Pharmacovigilance on cannabidiol as an antiepileptic agent

Untitled

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Contact Info

Product

Resources

About